C. Bartel

A phase IB, open-label dose-escalating study of the oral angiogenesis inhibitor PTK787/ZK 222584 (PTK/ZK), in combination with FOLFOX4 chemotherapy in patients with advanced colorectal cancer (2007)

Thomas, AL, Trarbach, T, Bartel, C, Laurent, D, Henry, A, Poethig, M, ...

Background: This open-label, phase IB study was undertaken to determine the safety/toxicity profile and recommended dose of oral once-daily PTK787/ZK 222584 (PTK/ZK) combined with...

A phase IB, open-label dose-escalating study of the oral angiogenesis inhibitor PTK787/ZK 222584 (PTK/ZK), in combination with FOLFOX4 chemotherapy in patients with advanced colorectal cancer (2007)

Thomas, AL, Trarbach, T, Bartel, C, Laurent, D, Henry, A, Poethig, M, ...

Background: This open-label, phase IB study was undertaken to determine the safety/toxicity profile and recommended dose of oral once-daily PTK787/ZK 222584 (PTK/ZK) combined with...

A phase IB, open-label dose-escalating study of the oral angiogenesis inhibitor PTK787/ZK 222584 (PTK/ZK), in combination with FOLFOX4 chemotherapy in patients with advanced colorectal cancer (2007)

Thomas, AL, Trarbach, T, Bartel, C, Laurent, D, Henry, A, Poethig, M, ...

Background: This open-label, phase IB study was undertaken to determine the safety/toxicity profile and recommended dose of oral once-daily PTK787/ZK 222584 (PTK/ZK) combined with...

Beyond mammography screening: quality assurance in breast cancer diagnosis (The QuaMaDi Project)

Katalinic, A, Bartel, C, Raspe, H, Schreer, I

As many breast cancer cases are detected outside mammographic screening, a multidisciplinary quality management (QuaMaDi) project involving gynaecologists, double reading by radiologists. and...